QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Q/C TECHNOLOGIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.50−0.04 (-7.10%)
Close on Oct 19, 2026
- Market cap
- $4.12M
- P/E (TTM)
- –
- Dividend yield
- –
Q/C TECHNOLOGIES, INC. revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | TTM Q2 17 | TTM Q1 17 | TTM Q4 16 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | – | – | – | – | – | – | – | $2.34M | $2.28M | $2.33M | – | – |
| Rest of World [Member] | – | – | $17.50K | – | – | – | $88.81K | $168.97K | $116.45K | $127.19K | – | – |
| United States | – | – | $1.56M | $1.75M | $1.88M | $1.89M | $1.58M | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Q/C Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.